The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 27, 2016
Filed:
Nov. 10, 2014
The United States of America, As Represented BY the Secretary of Agriculture, Washington, DC (US);
The University of Connecticut, Storrs, CT (US);
Manuel V. Borca, Westbrook, CT (US);
Lauren G. Holinka-Patterson, Deep River, CT (US);
Vivian K. O'Donnell, Old Saybrook, CT (US);
Guillermo S. Risatti, Westbrook, CT (US);
Douglas Gladu, Guilford, CT (US);
The United States of America, as Represented by the Secretary of Agriculture, Washington, DC (US);
The University of Connecticut, Storrs, CT (US);
Abstract
African swine fever virus (ASFV) is the etiological agent of a contagious and often lethal viral disease of domestic pigs. Control of ASF has been hampered by the unavailability of vaccines. Experimental vaccines have been derived from naturally occurring, cell culture-adapted, or genetically modified live attenuated ASFVs; however, these vaccines are only successful when protecting against homologous viruses. Among viral genes reported to be involved in virulence are components of the multi gene family (MGF). Here we report the construction of a recombinant ΔMGF virus derived from the highly virulent ASFV Georgia 2007 (ASFV-G) isolate. In vivo, ASFV-G ΔMGF administered intramuscularly (IM) to swine at either 10or 10HADare completely attenuated; the inoculated animals are completely asymptomatic. Animals infected with 10or 10HAD50 of ASFV-G ΔMGF are protected against the presentation of clinical disease when challenged at 28 days post infection with the virulent parental strain Georgia 2007.